Free Trial

Eton Pharmaceuticals (ETON) Competitors

Eton Pharmaceuticals logo
$19.62 -0.21 (-1.06%)
As of 11:28 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ETON vs. DYN, HRMY, IMCR, APGE, SRPT, AUPH, CDTX, VCEL, PAHC, and ARDX

Should you be buying Eton Pharmaceuticals stock or one of its competitors? The main competitors of Eton Pharmaceuticals include Dyne Therapeutics (DYN), Harmony Biosciences (HRMY), Immunocore (IMCR), Apogee Therapeutics (APGE), Sarepta Therapeutics (SRPT), Aurinia Pharmaceuticals (AUPH), Cidara Therapeutics (CDTX), Vericel (VCEL), Phibro Animal Health (PAHC), and Ardelyx (ARDX). These companies are all part of the "pharmaceutical products" industry.

Eton Pharmaceuticals vs. Its Competitors

Eton Pharmaceuticals (NASDAQ:ETON) and Dyne Therapeutics (NASDAQ:DYN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability.

Eton Pharmaceuticals has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500.

Dyne Therapeutics has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -7.10%. Eton Pharmaceuticals' return on equity of -0.73% beat Dyne Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Eton Pharmaceuticals-7.10% -0.73% -0.22%
Dyne Therapeutics N/A -64.12%-56.75%

In the previous week, Eton Pharmaceuticals had 4 more articles in the media than Dyne Therapeutics. MarketBeat recorded 4 mentions for Eton Pharmaceuticals and 0 mentions for Dyne Therapeutics. Eton Pharmaceuticals' average media sentiment score of 0.22 beat Dyne Therapeutics' score of 0.00 indicating that Eton Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Eton Pharmaceuticals Neutral
Dyne Therapeutics Neutral

27.9% of Eton Pharmaceuticals shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 14.9% of Eton Pharmaceuticals shares are held by insiders. Comparatively, 20.8% of Dyne Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Eton Pharmaceuticals has higher revenue and earnings than Dyne Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eton Pharmaceuticals$39.01M13.49-$3.82M-$0.16-122.63
Dyne TherapeuticsN/AN/A-$317.42M-$3.86-3.43

Eton Pharmaceuticals presently has a consensus price target of $29.67, indicating a potential upside of 51.21%. Dyne Therapeutics has a consensus price target of $34.07, indicating a potential upside of 157.59%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dyne Therapeutics is more favorable than Eton Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eton Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Dyne Therapeutics
0 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
3 Strong Buy rating(s)
3.06

Summary

Dyne Therapeutics beats Eton Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get Eton Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ETON and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ETON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ETON vs. The Competition

MetricEton PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$528.84M$3.13B$5.72B$10.40B
Dividend YieldN/A2.36%5.53%4.58%
P/E Ratio-123.2421.0076.4326.62
Price / Sales13.49255.87472.7192.34
Price / CashN/A46.3537.4661.85
Price / Book20.879.8013.276.45
Net Income-$3.82M-$52.73M$3.29B$271.39M
7 Day Performance10.97%4.70%2.60%3.06%
1 Month Performance13.41%6.23%4.65%7.62%
1 Year Performance241.22%18.77%74.34%30.20%

Eton Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ETON
Eton Pharmaceuticals
1.8741 of 5 stars
$19.62
-1.1%
$29.67
+51.2%
+240.1%$528.84M$39.01M-123.2420Positive News
DYN
Dyne Therapeutics
3.3464 of 5 stars
$12.86
-2.2%
$34.07
+164.9%
-61.9%$1.87BN/A-3.33100
HRMY
Harmony Biosciences
4.5372 of 5 stars
$32.50
+0.3%
$51.00
+56.9%
-16.2%$1.86B$714.73M10.48200Positive News
Gap Down
IMCR
Immunocore
1.9471 of 5 stars
$34.42
-2.3%
$56.89
+65.3%
+11.8%$1.78B$310.20M-86.05320
APGE
Apogee Therapeutics
2.229 of 5 stars
$36.86
-0.1%
$97.29
+163.9%
-33.9%$1.70BN/A-8.9291Positive News
SRPT
Sarepta Therapeutics
4.3462 of 5 stars
$17.47
+0.5%
$39.32
+125.1%
-85.6%$1.70B$1.90B-20.081,372Analyst Upgrade
AUPH
Aurinia Pharmaceuticals
2.7352 of 5 stars
$12.81
+0.5%
$12.00
-6.3%
+86.2%$1.68B$235.13M29.79300
CDTX
Cidara Therapeutics
3.3257 of 5 stars
$66.91
+2.0%
$64.14
-4.1%
+576.1%$1.66B$1.27M-6.0190News Coverage
Analyst Forecast
Gap Up
High Trading Volume
VCEL
Vericel
2.8622 of 5 stars
$31.42
-2.4%
$60.40
+92.2%
-32.7%$1.62B$237.22M261.86300
PAHC
Phibro Animal Health
4.4611 of 5 stars
$39.53
-0.2%
$28.40
-28.2%
+74.7%$1.61B$1.30B33.502,475Positive News
Insider Trade
ARDX
Ardelyx
4.2652 of 5 stars
$6.53
-1.2%
$11.70
+79.2%
+3.9%$1.59B$333.61M-28.3990

Related Companies and Tools


This page (NASDAQ:ETON) was last updated on 9/24/2025 by MarketBeat.com Staff
From Our Partners